Mark Sabag - 03 Mar 2025 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role: Executive Vice President, International Markets Commercial
Signature: /s/ Dov Bergwerk as attorney-in-fact for Mark Sabag
Issuer symbol: TEVA
Transactions as of: 03 Mar 2025
Net transactions value: $0
Form type: 4
Filing time: 05 Mar 2025, 16:16:04 UTC
Previous filing: 14 Feb 2025
Next filing: 06 Mar 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TEVA	Ordinary Shares	Options Exercise		+24,900	+12%		229,864	03 Mar 2025	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TEVA	Restricted Share Units	Options Exercise	$0	-24,900	-33%	$0.000000	49,801	03 Mar 2025	Ordinary Shares	24,900		Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2	Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3	Restricted share units were granted on March 3, 2023, with 24,900 vested on each of March 3, 2024 and March 3, 2025, 24,900 vesting on March 3, 2026, and 24,901 vesting on March 3, 2027.

Remarks:

Executive Vice President, International Markets Commercial